Multiple endocrine neoplasia type 2 differential diagnosis: Difference between revisions
Sergekorjian (talk | contribs) |
Irfan Dotani (talk | contribs) No edit summary |
||
Line 2: | Line 2: | ||
{{Multiple endocrine neoplasia type 2}} | {{Multiple endocrine neoplasia type 2}} | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Multiple endocrine neoplasia type 2 must be differentiated from other hereditary tumors such as [[medullary thyroid carcinoma]], C-cell hyperplasia, [[pheochromocytoma]], [[von Hippel Lindau syndrome]], hereditary paraganglioma-pheochromocytoma, polycythemia and paraganglioma/pheochromocytoma syndrome, [[neurofibromatosis type 1]], and [[multiple endocrine neoplasia type 1]] (MEN 1). | Multiple endocrine neoplasia type 2 must be differentiated from other hereditary tumors such as [[medullary thyroid carcinoma]], C-cell hyperplasia, [[pheochromocytoma]], [[von Hippel Lindau syndrome]], hereditary paraganglioma-pheochromocytoma, polycythemia and paraganglioma/pheochromocytoma syndrome, [[neurofibromatosis type 1]], and [[multiple endocrine neoplasia type 1]] (MEN 1). | ||
== | ==Differential Diagnosis== | ||
Multiple endocrine neoplasia type 2 must be differentiated from the following hereditary diseases. | Multiple endocrine neoplasia type 2 must be differentiated from the following hereditary diseases. | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 60%" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 60%" align=center | ||
Line 47: | Line 48: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category: | [[Category:Oncology | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 14:10, 21 July 2016
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 differential diagnosis On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 differential diagnosis |
FDA on Multiple endocrine neoplasia type 2 differential diagnosis |
CDC on Multiple endocrine neoplasia type 2 differential diagnosis |
Multiple endocrine neoplasia type 2 differential diagnosis in the news |
Blogs on Multiple endocrine neoplasia type 2 differential diagnosis |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Multiple endocrine neoplasia type 2 must be differentiated from other hereditary tumors such as medullary thyroid carcinoma, C-cell hyperplasia, pheochromocytoma, von Hippel Lindau syndrome, hereditary paraganglioma-pheochromocytoma, polycythemia and paraganglioma/pheochromocytoma syndrome, neurofibromatosis type 1, and multiple endocrine neoplasia type 1 (MEN 1).
Differential Diagnosis
Multiple endocrine neoplasia type 2 must be differentiated from the following hereditary diseases.
Disease | Definition |
---|---|
Medullary thyroid carcinoma | Medullary thyroid cancer (MTC) is a form of thyroid carcinoma which originates from the parafollicular cells (C cells), which produce the hormone calcitonin. |
C-cell hyperplasia | It is a genetic condition that causes proliferation of C cells of parathyroid gland. |
Pheochromocytoma | A neuroendocrine tumor of the medulla of the adrenal glands (originating in the chromaffin cells), or extra-adrenal chromaffin tissue that failed to involute after birth. |
von Hippel Lindau syndrome | An autosomal dominant genetic disorder causing abnormal growth of blood vessels in different parts of the body. |
Hereditary paraganglioma-pheochromocytoma syndrome | A genetic disorder causing abnormal growth of ganglions along with tumor of the medulla of adrenal gland. |
Polycythemia and paraganglioma/pheochromocytoma | A genetic disorder causing abnormal growth of ganglions and RBC cells. |
Neurofibromatosis type 1 | Neurofibromatosis type I is a tumor disorder that is caused by the mutation of a gene on chromosome 17 that is responsible for control of cell division causing tumors along the nervous system. Common symptoms of neurofibromatosis type I include scoliosis (curvature of the spine), learning disabilities, vision disorders, and epilepsy. |
Multiple endocrine neoplasia type 1 (MEN 1) | An autosomal dominant genetic disorder causing tumors of parathyroid, pancreas, and pituitary gland. |
Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/[1] |
References
- ↑ Jessica Marquard & Charis Eng (1993). "Multiple Endocrine Neoplasia Type 2". PMID 020301434.
[[Category:Oncology